Trump administration defends Medicare drug price talks in case brought by Novartis
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.
Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...
While Trump's tariffs could have a broad impact on healthcare prices, it is likely they will not have the devastating result ...
Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...
WASHINGTON, DC - OCTOBER 06: Activists protest the price of prescription drug costs in front of the ... [+] U.S. Department of Health and Human Services (HHS) building Your father’s rheumatoid ...
Colorado’s spending on highly effective but costly weight-loss drugs for state workers more than quadrupled from 2023 to 2024 — and costs have been doubling every six months. Now, the state ...
The Maryland House of Delegates has voted overwhelmingly to allow a state board to extend its mandate for lowering ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback